DE69523943D1 - Neue antithrombotische formulierung, verfahren zur herstellung und gebrauch davon - Google Patents

Neue antithrombotische formulierung, verfahren zur herstellung und gebrauch davon

Info

Publication number
DE69523943D1
DE69523943D1 DE69523943T DE69523943T DE69523943D1 DE 69523943 D1 DE69523943 D1 DE 69523943D1 DE 69523943 T DE69523943 T DE 69523943T DE 69523943 T DE69523943 T DE 69523943T DE 69523943 D1 DE69523943 D1 DE 69523943D1
Authority
DE
Germany
Prior art keywords
production
new antithrombotic
formulation
antithrombotic formulation
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69523943T
Other languages
English (en)
Other versions
DE69523943T2 (de
Inventor
Jan-Erik Loefroth
Anna-Lena Ungell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE69523943D1 publication Critical patent/DE69523943D1/de
Application granted granted Critical
Publication of DE69523943T2 publication Critical patent/DE69523943T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Cephalosporin Compounds (AREA)
DE69523943T 1994-12-02 1995-11-29 Neue antithrombotische formulierung, verfahren zur herstellung und gebrauch davon Expired - Fee Related DE69523943T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9404196A SE9404196D0 (sv) 1994-12-02 1994-12-02 New antithrombotic formulation
PCT/SE1995/001425 WO1996016671A1 (en) 1994-12-02 1995-11-29 New antithrombotic formulation, process for its manufacturing, and use thereof

Publications (2)

Publication Number Publication Date
DE69523943D1 true DE69523943D1 (de) 2001-12-20
DE69523943T2 DE69523943T2 (de) 2002-06-27

Family

ID=20396207

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69523943T Expired - Fee Related DE69523943T2 (de) 1994-12-02 1995-11-29 Neue antithrombotische formulierung, verfahren zur herstellung und gebrauch davon

Country Status (27)

Country Link
US (1) US5795896A (de)
EP (1) EP0799052B1 (de)
JP (1) JPH10513438A (de)
CN (1) CN1168635A (de)
AR (1) AR002254A1 (de)
AT (1) ATE208628T1 (de)
AU (1) AU689994B2 (de)
BR (1) BR9509853A (de)
CA (1) CA2206459A1 (de)
CZ (1) CZ147097A3 (de)
DE (1) DE69523943T2 (de)
DK (1) DK0799052T3 (de)
EE (1) EE03338B1 (de)
ES (1) ES2168395T3 (de)
FI (1) FI972332A (de)
HU (1) HU216631B (de)
IL (1) IL116153A (de)
IS (1) IS4483A (de)
NO (1) NO972475L (de)
NZ (1) NZ297118A (de)
PL (1) PL320692A1 (de)
PT (1) PT799052E (de)
SE (1) SE9404196D0 (de)
SK (1) SK61797A3 (de)
TR (1) TR199501517A2 (de)
WO (1) WO1996016671A1 (de)
ZA (1) ZA9510242B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
GB9526273D0 (en) * 1995-12-21 1996-02-21 Astra Ab New prodrugs
TW541316B (en) 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9602145D0 (sv) * 1996-05-31 1996-05-31 Astra Ab New improved formulation for treatment of thromboembolism
US6423334B1 (en) * 1997-10-01 2002-07-23 Elan Corporation, Plc Composition and method for enhancing transport across gastrointestinal tract cell layers
AR023510A1 (es) 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
SE9902550D0 (sv) * 1999-07-02 1999-07-02 Astra Ab New crystalline forms
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
MXPA03011538A (es) * 2001-06-14 2004-03-09 Otsuka Pharma Co Ltd Composicion medicinal que sustancialmente no causaria dano a la mucosa intestinal.
SE0103590D0 (sv) * 2001-10-26 2001-10-26 Astrazeneca Ab New Combination
SE0203349D0 (sv) * 2002-11-12 2002-11-12 Astrazeneca Ab New use
PT1569912E (pt) 2002-12-03 2015-09-15 Pharmacyclics Llc Derivados 2-(2-hidroxibifenil-3-il)-1h-benzoimidazole-5- carboxamidina como inibidores do fator viia
US7345093B2 (en) * 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
RU2354647C2 (ru) 2007-06-28 2009-05-10 Общество С Ограниченной Ответственностью "Бионика" Новые соединения, обладающие функцией ингибиторов тромбина, и фармацевтические композиции на их основе
EP2271347B1 (de) 2008-03-28 2016-05-11 Hale Biopharma Ventures, Llc Verabreichung von benzodiazepin-zusammensetzungen
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
US20100215730A1 (en) * 2009-02-20 2010-08-26 Intrepid Therapeutics, Inc. Compositions for Nasal Administration of Phenothiazines
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
EP2480208A1 (de) 2009-09-23 2012-08-01 Indu Javeri Verfahren zur herstellung von liposomen
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
ES2917973T3 (es) 2011-06-14 2022-07-12 Neurelis Inc Administración de benzodiacepina
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
US4568636A (en) * 1981-03-25 1986-02-04 Pentapharm Ag Tripeptide derivatives
US4395401A (en) * 1981-09-09 1983-07-26 Smithkline Beckman Corporation Renally active dipeptides
HU192646B (en) * 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
AU600226B2 (en) * 1985-02-04 1990-08-09 Merrell Pharmaceuticals Inc. Novel peptidase inhibitors
DE3505555A1 (de) * 1985-02-18 1986-09-11 Behringwerke Ag, 3550 Marburg Neue oligopeptidylargininolderivate und deren homologe, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel
PT84170B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas
DE3606480A1 (de) * 1986-02-28 1987-09-03 Behringwerke Ag Oligopeptidylnitrilderivate, diese enthaltende mittel, verfahren zu ihrer herstellung und ihre verwendung
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0362002B1 (de) * 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV Protease-Hemmer
ZA897514B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US5053392A (en) * 1989-12-01 1991-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel arginine, glycine, aspartic acid derivatives as platelet-aggregation inhibitors
US5110812A (en) * 1990-06-04 1992-05-05 Bristol-Myers Squibb Co. Azetidin-2-one derivatives as serine protease inhibitors
US5037819A (en) * 1990-06-04 1991-08-06 Bristol-Myers Squibb Company Azetidin-2-one derivatives as serine protease inhibitors
TW201303B (de) * 1990-07-05 1993-03-01 Hoffmann La Roche
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
GB9019558D0 (en) * 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
IL99527A (en) * 1990-09-28 1997-08-14 Lilly Co Eli Tripeptide antithrombotic agents
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
WO1992008709A1 (de) * 1990-11-15 1992-05-29 Pentapharm Ag Meta-substituierte phenylalanin-derivate
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
SE9102462D0 (sv) * 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
CZ333492A3 (en) * 1991-11-12 1993-09-15 Lilly Co Eli Dipeptide of l-azetidine-2-carboxylic acids and l-argininaldehyde, process of its preparation and pharmaceutical preparation in which said dipeptide is comprised
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives

Also Published As

Publication number Publication date
CZ147097A3 (cs) 1998-02-18
AU4191596A (en) 1996-06-19
IS4483A (is) 1997-05-16
NO972475D0 (no) 1997-05-30
JPH10513438A (ja) 1998-12-22
MX9703975A (es) 1997-09-30
WO1996016671A1 (en) 1996-06-06
HUT77655A (hu) 1998-07-28
PT799052E (pt) 2002-05-31
CN1168635A (zh) 1997-12-24
AU689994B2 (en) 1998-04-09
ES2168395T3 (es) 2002-06-16
BR9509853A (pt) 1997-12-30
EE03338B1 (et) 2001-02-15
US5795896A (en) 1998-08-18
FI972332A0 (fi) 1997-06-02
NO972475L (no) 1997-05-30
TR199501517A2 (tr) 1996-07-21
SK61797A3 (en) 1998-03-04
CA2206459A1 (en) 1996-06-06
NZ297118A (en) 1998-12-23
IL116153A0 (en) 1996-01-31
FI972332A (fi) 1997-06-02
DE69523943T2 (de) 2002-06-27
ATE208628T1 (de) 2001-11-15
AR002254A1 (es) 1998-03-11
SE9404196D0 (sv) 1994-12-02
PL320692A1 (en) 1997-10-27
EP0799052B1 (de) 2001-11-14
DK0799052T3 (da) 2002-02-25
HU216631B (hu) 1999-07-28
EP0799052A1 (de) 1997-10-08
IL116153A (en) 1999-11-30
ZA9510242B (en) 1996-06-03

Similar Documents

Publication Publication Date Title
DE69523943D1 (de) Neue antithrombotische formulierung, verfahren zur herstellung und gebrauch davon
DE69528111D1 (de) Biosensor und Verfahren zur Herstellung desselben
DE69429873D1 (de) Teilchenförmige aromazusammenstellungen und verfahren zur herstellung derselben
DE69532895D1 (de) Biomaterial und verfahren zu dessen herstellung
DE69530954D1 (de) Mikromechanisches Bauelement und Verfahren zur Herstellung desselben
DE69527054D1 (de) Retroreflektierender gegenstand und verfahren zur herstellung
DE69710487D1 (de) Stabiler standbeutel und verfahren zur herstellung
DE69535720D1 (de) Faserstoffbahn und verfahren zur dessen herstellung
DE69623926D1 (de) Kugelgelenk und verfahren zur herstellung
DE69417538D1 (de) Maleinsäurecopolymer, verfahren zur herstellung und dessen anwendung
DE69103230D1 (de) 1-Pyridylimidazolderivat und Verfahren zur Herstellung und Anwendung.
DE69835139D1 (de) Fäulnisverhindernde emulsionsbeschichtungszusammensetzung, verfahren zur herstellung und mit dieser fäulnisverhindernden zusammensetzung beschichteter gegenstand
DE69819015D1 (de) Norbonenpolymer und verfahren zur herstellung
DE69519739D1 (de) Epdm zusammensetzungen und verfahren zur herstellung davon
DE69534190D1 (de) Verfahren zur Herstellung von 1,2-Benzisothiazol-3-onen
DE69512365D1 (de) Wässerige Tintenzusammensetzung und Verfahren zur Herstellung derselben
DE69113025D1 (de) Drei neue nichtpolyglutamisierende deazaaminopterine und verfahren zur herstellung.
DE69511248D1 (de) Polycarbomate, verfahren zur herstellung von polycarbomaten und verfahren zur herstellung von polyisocyanaten
ATE290003T1 (de) Verfahren zur herstellung von pyrazolo-(4,3- d)pyrimidin-7-ones und zwischenprodukte davon
DE59503847D1 (de) Verfahren zur Herstellung von 3,5-Dimethylpyrazol-blockierten Polyisocyanaten
DE69622051D1 (de) Verfahren zur herstellung von 2,4-dihydroxy-pyridin und 2,4-dihydroxy-3-nitropyridin
DE69012731D1 (de) Oxydsupraleiter und verfahren zur herstellung.
DE69515697D1 (de) Blockcopolymere und verfahren zur herstellung
DE69511788D1 (de) Verfahren zur Herstellung von 1,1,1,3,3-Pentafluorpropan
DE69802099D1 (de) Mikromonochromator und verfahren für dessen herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee